CASE REPORT
DRESS syndrome associated with Type 2 Diabetes in a child: a case report
 
More details
Hide details
 
Submission date: 2015-03-04
 
 
Final revision date: 2015-04-27
 
 
Acceptance date: 2015-08-12
 
 
Publication date: 2016-01-15
 
 
Cent Eur J Immunol 2015;40(4):493-496
 
KEYWORDS
ABSTRACT
Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is an uncommon, life-threatening drug reaction. The basic findings are skin rash, multiorgan involvement, and eosinophilia. Most of the aromatic anticonvulsants, such as phenytoin, phenobarbital and carbamazepine can induce DRESS. Herein we report a 14-year-old patient with DRESS syndrome related to carbamazepine use. The patient presented with signs of involvement of the skin, lungs, liver, and microscopic hematuria. Carbamazepine treatment was discontinued; antihistamines and steroids were started. Hyperglycemia, commencing on the first dose of the steroid given, persisted even after the discontinuation of steroids and improvement of other signs. There were no signs of pancreatitis or type 1 diabetes clinically in laboratory tests. Her blood glucose levels were regulated at first with insulin and later with metformin. Within 1 year of follow-up, still regulated with oral antidiabetics, she has been diagnosed with type 2 diabetes. Formerly, long-term sequelae related to “drug rash with eosinophilia and systemic symptoms syndrome” such as hepatic and renal failure, type 1 diabetes mellitus, Grave’s disease, autoimmune hemolytic anemia, and lupus have also been reported. However, up to date, no cases with type 2 diabetes have been reported as long-term sequelae. To our knowledge, this is the first case in the literature presenting with type 2 diabetes as long-term sequelae.
REFERENCES (11)
1.
Cacoub P, Musette P, Descamps, et al. (2011): The DRESS Syndrome: A Literatüre Review. Am J Med 124: 588-597.
 
2.
Lee JH, Park HK, Heo J, et al. (2008): Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Induced by Celecoxib and Anti-tuberculosis Drugs. J Korean Med Sci 23: 521-525.
 
3.
Giri PP, Roy S, Bhattyacharya S, et al. (2011): DRESS Syndrome With Sepss, Acute Respratory Dstress Syndrome And Pneumomedastnum. Indian J Dermatol 56: 763-765.
 
4.
Bourgeois GP, Cafardi JA, Groysman V, Hugey LC (2012): A review of DRESS-associated myocarditis. J Am Acad Dermatol 66: 229-236.
 
5.
Alkhateeb H, Said S, Cooper CJ, et al. (2013): DRESS syndrome following ciprofloxacin exposure: An unusual association. Am J Case Rep 14: 526-528.
 
6.
Zou CC, Liang L, Fu JF (2008): Type 1 diabetes mellitus in a child with phenobarbital hypersensitivity syndrome. J Endocrinol Invest 31: 360-363.
 
7.
Omairi NE, Abourazzak S, Chaouki S, et al. (2014): Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by carbamazepine: a case report and literature review. Pan African Medical Journal 18: 9.
 
8.
Natkunarajah J, Goolamali S, Craythorne E, et al. (2011): Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol 21: 385-391.
 
9.
Chen YC, Chang CY, Cho YT, et al. (2013): Long-term sequelae of drug reaction with eosinophilia and systemis symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 68: 459-465.
 
10.
Ushigome Y, Kano Y, Ishida T, et al. (2013): Short and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol 68: 721-728.
 
11.
Dubois-Laforgue D, Moachon L, Laude H, Timsit J (2013). Fulminant type 1 diabetes in the course of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome. Diabetes Care 36: 68.
 
eISSN:1644-4124
ISSN:1426-3912
Journals System - logo
Scroll to top